# E2F1

## Overview
E2F1 is a gene that encodes the E2F transcription factor 1, a pivotal protein involved in the regulation of the cell cycle and apoptosis. As a member of the E2F family of transcription factors, E2F1 plays a crucial role in controlling the transition from the G1 phase to the S phase of the cell cycle by activating genes essential for DNA synthesis and cell proliferation (Field1996E2F1). The E2F1 protein is characterized by several structural domains, including a helix-loop-helix domain and a C-terminal acidic domain, which facilitate its interactions with other regulatory proteins such as the retinoblastoma protein (pRb) (Cress1993A). E2F1's function is tightly regulated through interactions with various proteins and complexes, including cyclin A/CDK2 and Sp1, which modulate its activity in cell cycle progression and apoptosis (Lin1996Cell; Xu1994Cyclin). Clinically, E2F1 is significant due to its dual role as both an oncogene and a tumor suppressor, with its dysregulation implicated in the progression of several cancers, including melanoma and gliomas (Alonso2008E2F1; Khan2017Unraveling).

## Structure
The E2F1 protein is characterized by several structural motifs essential for its regulatory functions. The primary structure includes specific amino acid sequences forming distinct domains: a basic domain (amino acids 109 to 127), a helix-loop-helix domain (amino acids 128 to 181), a leucine repeat (amino acids 199 to 234), and a C-terminal acidic domain (amino acids 368 to 437) (Cress1993A). The helix-loop-helix domain is critical for DNA binding, and mutations in this domain can abolish transcriptional activity by disrupting DNA-binding capacity (Cress1993A). The C-terminal acidic domain is crucial for interactions with regulatory proteins such as Rb, p107, and adenovirus E4, with these interactions being mutually exclusive (Cress1993A).

The E2F1 protein also contains a marked-box domain, which is important for DNA bending, although not required for DNA binding (Cress1996A). This domain contributes to the DNA-bending activity of E2F1, which is crucial for transcriptional activation (Cress1996A). E2F1 can form complexes with other proteins, potentially as part of a heterodimeric complex, which may contribute to its regulatory functions (Cress1993A).

## Function
E2F1 is a transcription factor that plays a critical role in regulating the cell cycle, particularly in the transition from the G1 phase to the S phase. It functions by binding to specific DNA sequences and activating genes necessary for DNA synthesis and cell cycle progression (Field1996E2F1). E2F1 is primarily active in the nucleus, where it regulates the transcription of genes involved in DNA replication and cell proliferation (Lin1996Cell).

In healthy human cells, E2F1 is involved in promoting cell proliferation by interacting with the retinoblastoma protein (pRb) and other growth-regulatory proteins. This interaction is crucial for the release of E2F1 from pRb, allowing it to activate target genes necessary for S phase entry (Dimri2000Regulation). E2F1 also plays a role in inducing a senescence-like phenotype when overexpressed, which acts as a checkpoint to prevent tumorigenesis. This senescence response is mediated through the induction of the p14ARF tumor suppressor, which stabilizes p53 and leads to cell cycle arrest (Dimri2000Regulation).

E2F1's ability to regulate both cell proliferation and senescence highlights its dual role in maintaining cellular homeostasis and preventing uncontrolled cell growth (Dimri2000Regulation).

## Clinical Significance
The E2F1 gene plays a significant role in cancer progression and is implicated in various malignancies due to its dual function as both an oncogene and a tumor suppressor. Alterations in E2F1 expression or function can lead to uncontrolled cell proliferation, contributing to the development of cancers such as melanoma, breast, lung, and prostate cancer (Knoll2012The; Khan2017Unraveling). In melanoma, E2F1 overexpression is associated with increased invasiveness and metastasis, partly through its interaction with the epidermal growth factor receptor (EGFR) (Pützer2010Predicting). 

E2F1 is also involved in the epithelial-mesenchymal transition (EMT), a process crucial for cancer metastasis, by interacting with non-coding RNAs and other signaling pathways (Khan2017Unraveling). In gliomas, E2F1 is part of the Rb/E2F1 pathway, which is often deregulated, leading to 'oncogene addiction' where cancer cells depend on E2F1 for survival and growth (Alonso2008E2F1). 

Additionally, E2F1's role in apoptosis is context-dependent, as it can induce cell death or promote tumorigenesis depending on the genetic environment. This complexity is further influenced by microRNAs that regulate E2F1 expression, impacting its function in various cancers (Knoll2012The).

## Interactions
E2F1 interacts with several proteins and complexes that regulate its function in cell cycle progression and apoptosis. It forms a stable complex with cyclin A/CDK2, which inhibits the DNA-binding activity of the E2F1/DP-1 complex through phosphorylation. This interaction is direct and does not require the kinase-active form of CDK2, although the kinase activity is necessary for inhibiting DNA binding (Xu1994Cyclin). The binding region for cyclin A/CDK2 is located within the N-terminal 124 amino acids of E2F1 (Xu1994Cyclin).

E2F1 also interacts with the retinoblastoma protein (Rb), which inhibits E2F1-induced apoptosis through direct binding. This interaction is crucial for the repression of apoptotic genes, as the Rb-E2F1 complex acts as a repressor unit (Hsieh1997E2F1induced). E2F1 can bind to the Sp1 protein, enhancing E2F-dependent transcription. This interaction is specific to a region between amino acids 88 and 191 of E2F1 and is cell cycle-regulated, peaking in mid-to-late G1 phase (Lin1996Cell). These interactions highlight E2F1's role in regulating transcription and cell cycle dynamics.


## References


[1. (Field1996E2F1) Seth J Field, Fong-Ying Tsai, Frank Kuo, Ana M Zubiaga, William G Kaelin, David M Livingston, Stuart H Orkin, and Michael E Greenberg. E2f-1 functions in mice to promote apoptosis and suppress proliferation. Cell, 85(4):549–561, May 1996. URL: http://dx.doi.org/10.1016/S0092-8674(00)81255-6, doi:10.1016/s0092-8674(00)81255-6. This article has 989 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/S0092-8674(00)81255-6)

[2. (Cress1996A) W. Douglas Cress and Joseph R. Nevins. A role for a bent dna structure in e2f-mediated transcription activation. Molecular and Cellular Biology, 16(5):2119–2127, May 1996. URL: http://dx.doi.org/10.1128/mcb.16.5.2119, doi:10.1128/mcb.16.5.2119. This article has 52 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.16.5.2119)

[3. (Dimri2000Regulation) Goberdhan P. Dimri, Koji Itahana, Meileen Acosta, and Judith Campisi. Regulation of a senescence checkpoint response by the e2f1 transcription factor and p14arf tumor suppressor. Molecular and Cellular Biology, 20(1):273–285, January 2000. URL: http://dx.doi.org/10.1128/mcb.20.1.273-285.2000, doi:10.1128/mcb.20.1.273-285.2000. This article has 311 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.20.1.273-285.2000)

[4. (Khan2017Unraveling) Faiz M. Khan, Stephan Marquardt, Shailendra K. Gupta, Susanne Knoll, Ulf Schmitz, Alf Spitschak, David Engelmann, Julio Vera, Olaf Wolkenhauer, and Brigitte M. Pützer. Unraveling a tumor type-specific regulatory core underlying e2f1-mediated epithelial-mesenchymal transition to predict receptor protein signatures. Nature Communications, August 2017. URL: http://dx.doi.org/10.1038/s41467-017-00268-2, doi:10.1038/s41467-017-00268-2. This article has 77 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-017-00268-2)

[5. (Cress1993A) W. Douglas Cress, David G. Johnson, and Joseph R. Nevins. A genetic analysis of the e2f1 gene distinguishes regulation by rb, p107, and adenovirus e4. Molecular and Cellular Biology, 13(10):6314–6325, October 1993. URL: http://dx.doi.org/10.1128/mcb.13.10.6314-6325.1993, doi:10.1128/mcb.13.10.6314-6325.1993. This article has 2 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.13.10.6314-6325.1993)

[6. (Pützer2010Predicting) Brigitte M Pützer, Marc Steder, and Vijay Alla. Predicting and preventing melanoma invasiveness: advances in clarifying e2f1 function. Expert Review of Anticancer Therapy, 10(11):1707–1720, November 2010. URL: http://dx.doi.org/10.1586/era.10.153, doi:10.1586/era.10.153. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1586/era.10.153)

[7. (Knoll2012The) Susanne Knoll, Stephan Emmrich, and Brigitte M. Pützer. The E2F1-miRNA Cancer Progression Network, pages 135–147. Springer Netherlands, December 2012. URL: http://dx.doi.org/10.1007/978-94-007-5590-1_8, doi:10.1007/978-94-007-5590-1_8. This article has 30 citations.](https://doi.org/10.1007/978-94-007-5590-1_8)

[8. (Xu1994Cyclin) Min Xu, Kelly-Ann Sheppard, Cheng-Yuan Peng, Amy S. Yee, and Helen Piwnica-Worms. Cyclin a/cdk2 binds directly to e2f-1 and inhibits the dna-binding activity of e2f-1/dp-1 by phosphorylation. Molecular and Cellular Biology, 14(12):8420–8431, December 1994. URL: http://dx.doi.org/10.1128/mcb.14.12.8420-8431.1994, doi:10.1128/mcb.14.12.8420-8431.1994. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.14.12.8420-8431.1994)

[9. (Hsieh1997E2F1induced) J K Hsieh, S Fredersdorf, T Kouzarides, K Martin, and X Lu. E2f1-induced apoptosis requires dna binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes &amp; Development, 11(14):1840–1852, July 1997. URL: http://dx.doi.org/10.1101/gad.11.14.1840, doi:10.1101/gad.11.14.1840. This article has 220 citations.](https://doi.org/10.1101/gad.11.14.1840)

[10. (Alonso2008E2F1) Marta M. Alonso, Ramon Alemany, Juan Fueyo, and Candelaria Gomez-Manzano. E2f1 in gliomas: a paradigm of oncogene addiction. Cancer Letters, 263(2):157–163, May 2008. URL: http://dx.doi.org/10.1016/j.canlet.2008.02.001, doi:10.1016/j.canlet.2008.02.001. This article has 38 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.canlet.2008.02.001)

[11. (Lin1996Cell) Shiaw-Yih Lin, Adrian Rhys Black, Dusan Kostic, Sanja Pajovic, Carol N. Hoover, and Jane Clifford Azizkhan. Cell cycle-regulated association of e2f1 and sp1 is related to their functional interaction. Molecular and Cellular Biology, 16(4):1668–1675, April 1996. URL: http://dx.doi.org/10.1128/MCB.16.4.1668, doi:10.1128/mcb.16.4.1668. This article has 371 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.16.4.1668)